A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
brief summary
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available). The main goals of this study are: 1. To find the best dose levels (DLs) for the combination of BNT326 and pumitamig. 2. To look at how well participants with advanced NSCLC tolerate the combination therapy (for example, which side effects participants experience and how severe they are). 3. To look at how well the combination therapy works to shrink the tumor in participants with advanced NSCLC.
detailed description
Part 1 is a combination dose finding part. Participants will receive one of six combination DLs to evaluate and establish safe combination DLs of BNT326 with pumitamig, and to define the recommended Phase 2 combination dose.
Part 2a is a dose expansion part to evaluate the preliminary efficacy, safety, and tolerability.
Part 2b is a randomized dose optimization and contribution of components part.
Parts 1, Part 2a (Cohort A) and Part 2b (Cohort C) will enroll participants with previous exposure to therapy for advanced/metastatic disease. Part 2a (Cohort B) and Part 2b (Cohort D) will enroll participants without prior systemic treatment for advanced/metastatic disease.
The sponsor, having heard the internal review committee (IRC), will determine the DLs for each arm in Part 2b Cohorts C and D based on data generated from Parts 1 and 2a. The DLs chosen for Part 2b Cohorts C and D will not exceed the highest dose level investigated in this study.
Parts 1 and 2a will be non-randomized. In Part 2b, participants will be randomized to different treatments within each cohort.
The study consists of a screening period, a treatment period, a safety follow-up period, an efficacy follow-up period, and a long-term survival follow-up. Participants will receive study treatment until disease progression, withdrawal of consent, termination of the study by the sponsor, unacceptable toxicity, or for a maximum duration of 24 months, whichever occurs first. If a participant continues to derive clinical benefit after having reached the maximum treatment period of 24 months, continuation of study treatment will be considered on a case-by-case after discussion with the sponsor.
For each study participant, the treatment and follow-up periods are projected to be completed within \~36 months, unless the participant is continuing to benefit from treatment per investigator's recommendation and upon sponsor approval.
official title
A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)